Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Bristol Falls Further Behind Merck In NSCLC By Pulling Early Combo Filing

Executive Summary

Bristol-Myers Squibb's decision not to seek accelerated FDA approval for its Opdivo/Yervoy combo in early lung cancer shocked investors - but analysts still expect a filing to come, albeit later than first thought.


Related Content

Merck Stretches Lead As EU Approves Keytruda In First-Line NSCLC
4Q Pharma Results Preview, Part 2: Pfizer, Lilly, Roche, AstraZeneca, Merck, Amgen, Novo
Under Fire, Bristol Plans To Pick Up The IO Pieces
Patent Settlement Offers Some Salve For Bristol’s PD-1 Wounds
AstraZeneca Updates MYSTIC Plan In Bid To Challenge Merck In NSCLC
Bristol Still Rules Immuno-Oncology, But For How Long?
'Total Disaster' In First-Line Lung Cancer For BMS's Opdivo
What's Next For Bristol's Opdivo/Yervoy Combination


Related Companies